Financial Data and Key Metrics Changes - ClearPoint Neuro reported total revenues of $16.3 million for the year ended December 31, 2021, a 27% increase from $12.8 million in 2020 [7] - The company achieved a gross margin of 69% for 2021, down from 71% in 2020, primarily due to increased overhead costs [9] - For Q4 2021, total revenues were approximately $4.3 million, a 15% increase from $3.7 million in Q4 2020 [14] Business Line Data and Key Metrics Changes - Functional neurosurgery navigation revenue increased by 30% to $8.1 million in 2021, up from $6.2 million in 2020 [8] - Biologics and drug delivery revenue rose by 31% to $6.8 million in 2021, compared to $5.2 million in 2020, driven by increased commitments from pharmaceutical partners [8] - Capital equipment and software revenue remained stable at $1.4 million for 2021, consistent with 2020 [9] Market Data and Key Metrics Changes - The company reported a cash and cash equivalent balance of $54.1 million at the end of December 2021, compared to $20.1 million at the end of 2020, primarily due to a public offering completed in February 2021 [19] - ClearPoint is actively working on more than 35 different indications, with an estimated market potential exceeding $12 billion annually [41] Company Strategy and Development Direction - The company focuses on four pillars of growth: biologics and drug delivery, functional neurosurgery navigation, therapy and access products, and achieving global scale [6][20] - ClearPoint plans to continue expanding its partnerships in the biologics and drug delivery segment, with expectations for initial commercial gene therapy approvals in 2022 [22] - The company aims to enhance its product offerings, including the SmartFrame array and other innovative technologies, to solidify its position in the neurosurgery market [28][30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of the Delta and Omicron variants on elective procedures but expressed optimism for continued growth in 2022 [6][42] - The company reiterated its full-year 2022 revenue guidance of $20 million to $22 million, reflecting growth of 23% to 35% [42] - Management highlighted the importance of maintaining a strong cash position to navigate uncertainties in the operating environment [45] Other Important Information - Research and development costs increased by 92% to $9 million in 2021, primarily due to personnel costs and product development expenses [10] - General and administrative expenses rose by 66% to $8.8 million in 2021, driven by increases in share-based compensation and other operational costs [12] Q&A Session Summary Question: Can you provide expectations around growth in different business lines? - Management expects biologics to be the fastest-growing segment, potentially nearing functional neurosurgery revenue [48] Question: How should we think about revenue recognition across the year given Omicron's impact? - Management noted that January and February saw muted sales due to Omicron, but expects a return to normal in March [51] Question: What is the expected timeline for SmartFrame Array software clearance? - Management anticipates FDA approval in the second quarter of 2022, with first clinical cases expected in the second half of the year [57] Question: How is ClearPoint positioned in FDA approval documentation? - Management indicated that ClearPoint's technology may not be specifically named but will likely be recognized as a leader in MRI-guided procedures [62] Question: What is the expected contribution from new offerings to revenue growth? - Management stated that new offerings are not significantly included in the 2022 revenue guidance, with growth expected more from service offerings [75]

●● ..... ..... ●● CLEARPOINT® NEURO WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY." Nasdaq: CLPT November 2021 Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning o ...

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants Joseph Burnett - President and Chief Executive Officer Danilo D’Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Bjorn Ng - 10x Capital Operator Greetings and welcome to the ClearPoint Neuro Inc. Third Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____to _____ Commission file number: 001-34822 ClearPoint Neuro, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 58-2394628 (State or ...

[PART I – FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) This section presents the company's condensed consolidated financial statements and management's discussion and analysis of financial condition and results of operations [Financial Statements](index=4&type=section&id=ITEM%201.%20FINANCIAL%20STATEMENTS) The financial statements for June 30, 2021, reflect increased assets and revenue, driven by a public offering, despite widening net losses from higher operating expenses [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows a substantial increase in total assets and cash, primarily from a public offering, leading to a significant improvement in stockholders' equity Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2021 (Unaudited) | December 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $61,524 | $20,099 | | Total current assets | $68,509 | $25,462 | | Total assets | $72,326 | $29,518 | | **Liabilities & Equity** | | | | Total liabilities | $24,360 | $27,141 | | Total stockholders' equity | $47,966 | $2,377 | | Total liabilities and stockholders' equity | $72,326 | $29,518 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Revenue increased for both three and six-month periods, but net losses widened significantly due to higher operating expenses, particularly in R&D Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2021 | Q2 2020 | Six Months 2021 | Six Months 2020 | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $3,413 | $2,478 | $7,443 | $5,593 | | Gross profit | $2,290 | $1,676 | $4,904 | $3,860 | | Operating loss | $(3,407) | $(1,475) | $(5,588) | $(2,684) | | Net loss | $(3,743) | $(1,661) | $(6,281) | $(3,716) | | Net loss per share | $(0.17) | $(0.11) | $(0.31) | $(0.24) | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Stockholders' equity significantly increased due to net proceeds from a public offering and convertible note conversion, despite a net loss - A public offering of common stock in the first half of 2021 raised approximately **$46.8 million**[24](index=24&type=chunk) - A **$7.5 million** principal amount of the 2020 senior secured convertible note was converted into approximately **1.26 million** shares of common stock[24](index=24&type=chunk)[30](index=30&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash increased significantly due to substantial financing activities, primarily a public stock offering, offsetting cash used in operations Cash Flow Summary for the Six Months Ended June 30 (in thousands) | Cash Flow Category | 2021 | 2020 | | :--- | :--- | :--- | | Net cash from operating activities | $(5,849) | $(4,039) | | Net cash from investing activities | $(5) | $(441) | | Net cash from financing activities | $47,279 | $14,816 | | **Net change in cash** | **$41,425** | **$10,336** | | Cash, beginning of period | $20,099 | $5,696 | | **Cash, end of period** | **$61,524** | **$16,032** | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail business operations, COVID-19 impact, improved liquidity from financing, and key accounting policies for revenue, inventory, and debt [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=21&type=section&id=ITEM%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS.) MD&A discusses revenue growth from surgical recovery and partner activity, widening losses due to R&D investments, and strengthened liquidity from a public offering [Overview](index=21&type=section&id=Overview) ClearPoint Neuro, a medical device company, focuses on MRI-guided brain surgeries and has incurred significant accumulated deficits from R&D investments - The company's principal product is the ClearPoint system, which enables minimally invasive surgical procedures in the brain under direct MRI guidance[123](index=123&type=chunk) - As of June 30, 2021, the company had an accumulated deficit of approximately **$126 million**[124](index=124&type=chunk) [Factors Which May Influence Future Results of Operations](index=21&type=section&id=Factors%20Which%20May%20Influence%20Future%20Results%20of%20Operations) Future results are primarily influenced by the unpredictable impact of the COVID-19 pandemic, particularly on elective surgical procedures - The COVID-19 pandemic led to the postponement or cancellation of elective surgical procedures, which historically represent about **80%** of procedures using the ClearPoint system[126](index=126&type=chunk) - The impact of new COVID-19 variants, like the Delta variant, is unpredictable and could result in the reinstatement of business restrictions, adversely affecting the company[126](index=126&type=chunk) [Key Performance Indicators](index=22&type=section&id=Key%20Performance%20Indicators) Key performance indicators show significant increases in functional neurosurgery case volume and biologics partners, reflecting pandemic recovery Key Performance Indicator Changes | Indicator | Q2 2021 vs Q2 2020 | H1 2021 vs H1 2020 | | :--- | :--- | :--- | | Case Volume | +96% (249 vs 127) | +50% (463 vs 308) | - The number of biologics and drug delivery partners increased from approximately **20** as of June 30, 2020, to approximately **35** as of June 30, 2021[130](index=130&type=chunk) - The number of Active Surgery Centers was over **60** as of June 30, 2021, comparable to the prior year, with the lack of growth attributed to the COVID-19 pandemic[129](index=129&type=chunk) [Results of Operations](index=24&type=section&id=Results%20of%20Operations) Revenue increased due to surgical recovery and partner growth, but rising operating expenses, especially R&D, led to wider net losses [Comparison of Three Months Ended June 30, 2021 and 2020](index=24&type=section&id=Three%20Months%20Ended%20June%2030%2C%202021%20Compared%20to%20the%20Three%20Months%20Ended%20June%2030%2C%202020) Q2 2021 revenue increased due to resumed surgeries, but operating expenses, particularly R&D, surged, resulting in a significantly wider net loss Q2 2021 vs Q2 2020 Financial Results (in thousands) | Metric | Q2 2021 | Q2 2020 | % Change | | :--- | :--- | :--- | :--- | | Total revenue | $3,413 | $2,478 | 38% | | Gross profit | $2,290 | $1,676 | 37% | | Research and development costs | $2,123 | $812 | 161% | | Net loss | $(3,743) | $(1,661) | 125% | - The increase in revenue was primarily due to a **74%** increase in functional neurosurgery navigation and therapy revenue, reflecting the resumption of elective surgical procedures that were postponed in 2020 due to COVID-19[145](index=145&type=chunk) [Comparison of Six Months Ended June 30, 2021 and 2020](index=25&type=section&id=Six%20Months%20Ended%20June%2030%2C%202021%20Compared%20to%20the%20Six%20Months%20Ended%20June%2030%2C%202020) H1 2021 revenue increased from neurosurgery and biologics, but surging R&D expenses led to a significantly wider net loss H1 2021 vs H1 2020 Financial Results (in thousands) | Metric | H1 2021 | H1 2020 | % Change | | :--- | :--- | :--- | :--- | | Total revenue | $7,443 | $5,593 | 33% | | Gross profit | $4,904 | $3,860 | 27% | | Research and development costs | $3,687 | $1,631 | 126% | | Net loss | $(6,281) | $(3,716) | 69% | - Biologics and drug delivery revenue increased **39%** to **$3.0 million** for the six-month period, driven by higher product and service sales related to customer-sponsored clinical trials[159](index=159&type=chunk) [Liquidity and Capital Resources](index=27&type=section&id=Liquidity%20and%20Capital%20Resources) Despite historical losses, liquidity significantly improved with a public offering, providing sufficient capital for at least the next twelve months - On February 23, 2021, the company completed a public offering of common stock, raising net proceeds of approximately **$46.8 million**[171](index=171&type=chunk) - Management believes that cash and cash equivalent balances at June 30, 2021, are sufficient to support operations and meet obligations for at least the next twelve months[172](index=172&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=29&type=section&id=ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK.) Market risk is primarily interest rate sensitivity on investments and variable-rate debt, with foreign currency risk currently not material - The company's primary market risk is interest rate sensitivity on its investments and variable-rate debt[185](index=185&type=chunk) - The **$10.0 million** First Closing Note has a LIBOR floor of **2.00%**, mitigating risk from rising interest rates while LIBOR is below that level[187](index=187&type=chunk) - Foreign currency risk is not currently material as sales are predominantly in U.S. dollars[188](index=188&type=chunk) [Controls and Procedures](index=29&type=section&id=ITEM%204.%20CONTROLS%20AND%20PROCEDURES.) Management concluded that disclosure controls and procedures were effective, with no material changes to internal control over financial reporting - The principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective as of June 30, 2021[189](index=189&type=chunk) - No changes in internal control over financial reporting occurred during the quarter ended June 30, 2021, that materially affected, or are reasonably likely to materially affect, internal controls[190](index=190&type=chunk) [PART II – OTHER INFORMATION](index=30&type=section&id=PART%20II%20%E2%80%93%20OTHER%20INFORMATION) Part II covers legal proceedings, risk factors, equity sales, and exhibits, providing additional context beyond the financial statements [Legal Proceedings](index=30&type=section&id=Item%201.%20Legal%20Proceedings) No legal proceedings were reported during the period - None[193](index=193&type=chunk) [Risk Factors](index=30&type=section&id=Item%201A.%20Risk%20Factors) No material changes to previously disclosed risk factors were reported - There have been no material changes to the risk factors disclosed in the 2020 Form 10-K[195](index=195&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=30&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities were reported during the period - None[197](index=197&type=chunk) [Exhibits](index=31&type=section&id=Item%206.%20Exhibits) The report includes various exhibits, such as the 2021 Employee Stock Purchase Plan and CEO/CFO certifications - Exhibits filed with the report include the company's 2021 Employee Stock Purchase Plan and certifications from the CEO and CFO[205](index=205&type=chunk)

Company Overview - ClearPoint Neuro operates as both a biologics & drug delivery company with a potential market exceeding $1 billion, expecting its first indication in 2022 [4] - The company also functions as a medical device company with an existing market opportunity of over $500 million, anticipating more than 5 new products in the next 2 years [4] - In 2020, ClearPoint Neuro's revenue reached $12.8 million [5] - The company's gross margin stands at 67% [5] Biologics & Drug Delivery - The estimated market opportunity for gene therapy using the ClearPoint platform is $1.5 billion [15] - Specific indications targeted include AADC Deficiency (~$12 million), Friedreich's Ataxia (~$60 million), Angelman Syndrome (~$72 million), and Parkinson's Disease (~$1.2 billion) [15] - Other indications include Huntington Disease, Diffuse Intrinsic Pontine Glioma (~$20 million), Multiple System Atrophy (~$90 million), ALS (~$120 million), and Glioblastoma (~$2.4 billion) [15] Neuro Navigation (DBS) - The total current addressable U S market for Deep Brain Stimulation (DBS) navigation is $72 million [19] - The DBS market is experiencing a growth rate of 10% [19] New Therapy Devices - The total current addressable market for Laser Therapy in Epilepsy and Tumors is $360 million, growing at 20+% [22] Financial Performance - Estimated FY21 revenue is $17.5 million [28, 29]

Financial Data and Key Metrics Changes - Total revenue for Q2 2021 was $3.4 million, an increase of $0.9 million or 38% compared to $2.5 million in Q2 2020 [7] - Gross margin for Q2 2021 was 67%, slightly down from 68% in Q2 2020 [11] - Cash and cash equivalents totaled $61.5 million as of June 30, 2021, compared to $20.1 million at the end of 2020, primarily due to a public offering [15] Business Line Data and Key Metrics Changes - Functional neurosurgery navigation therapy revenue increased 74% to $1.9 million in Q2 2021 from $1.1 million in Q2 2020, driven by the resumption of elective surgical procedures [8] - Biologics and drug delivery revenue rose 19% to $1.4 million in Q2 2021 from $1.2 million in Q2 2020, attributed to the re-establishment of clinical trial timelines [9] - Capital equipment and software revenue remained stable at $0.2 million for both Q2 2021 and Q2 2020, affected by capital headwinds and delays [10] Market Data and Key Metrics Changes - The company reported a record of 249 procedures covered in Q2 2021, a 98% increase from 126 procedures in the same quarter last year [18] - The company noted potential disruptions in elective procedures due to the COVID Delta variant, particularly in states like Texas and Florida [19] Company Strategy and Development Direction - The company is focused on four pillars of growth: functional neurosurgery navigation, biologics and drug delivery, therapeutic products, and achieving global scale [6] - Recent partnerships with Blackrock Neurotech and adeor are aimed at enhancing the operating room capabilities and expanding product offerings [17][28] - The company plans to continue expanding its biologics and drug delivery partnerships, with a goal of achieving initial commercial gene therapy approval in 2022 [35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery of elective procedures and expects significant revenue growth in the second half of 2021 [44] - The company reaffirmed its revenue guidance for the year, projecting between $16 million and $17.5 million [41] - Management acknowledged challenges due to the COVID Delta variant but noted that most hospitals have resumed operations [84] Other Important Information - Research and development costs increased significantly to $2.1 million in Q2 2021, up 177% from $0.8 million in Q2 2020 [12] - The company has added 50 new employees to support product development and global expansion efforts [15] Q&A Session Summary Question: What are the drivers for sequential growth through year-end? - Management expects significant revenue growth in the third quarter, citing replenishment orders and a record month in July for biologics and case volume [44] Question: How will the Array product be implemented across established sites? - Management believes the Array system will benefit both existing and new customers, particularly for laser ablation procedures [45][46] Question: Update on the biologic approval timeline? - Management confirmed that a partner is still expecting to submit their BLA in 2021, with potential approval in 2022 [48] Question: Progress on site activation in Europe? - Management reported that installations have resumed in Europe, with expectations for additional installations by year-end [55] Question: Direct-to-patient marketing for asleep DBS procedures? - Management is making progress in educating neurologists on the ClearPoint procedure and its applications [59] Question: Interest in new partnerships for global expansion? - Management noted increased interest from European pharmaceutical partners and plans for cautious expansion into Asia [81] Question: Status of clinical trials and new initiations? - Management indicated that most hospitals have resumed trials, with ongoing enrollment expected in the second half of the year [86]

Company Overview - ClearPoint Neuro operates as both a biologics & drug delivery company with a potential market exceeding $1 billion, experiencing 109% growth in 2020 despite COVID-19 [3] - It also functions as a medical device company with an existing market opportunity of over $500 million, anticipating the launch of 5+ new products within the next 2 years [3] - The company's key products are supported by a "razor/razorblade" model, with over 85% of revenue derived from single-use disposables and services [5] Technology and Platform - ClearPoint Neuro's platform leverages live MR imaging for real-time guidance and confirmation with sub-millimetric accuracy [7] - The ClearPoint 'Maestro' Brain Model, jointly developed with Philips, enables point-based correspondence across multiple subjects and serves as the foundation for future navigation tools [9] - The ClearPoint platform is compatible with all major MRI scanner brands, including Siemens, Philips, and IMRIS [13] Market Opportunities and Growth Strategy - The company estimates a $1.5 billion market opportunity in biologics & drug delivery, targeting indications like Glioblastoma, Parkinson's Disease, and Huntington's Disease [17] - In Neuro Navigation (DBS), the total current addressable U S market is $72 million (6,000 cases x $12,000/case), with a 10% growth rate [22] - The total current addressable market for ClearPoint Neuro Laser Therapy is $360 million (20,000 cases x $18,000/case), growing at a rate of 20+% [28] - The company's 4-pillar growth strategy aims for a potential addressable market of over $1 billion by 2025, targeting over 150,000 procedures per year [34] Financial Performance - The company's estimated FY21 revenue is $17.5 million [36] - Procedure volume has grown at a 33%+ CAGR from 2013-2019 [37] - In 2021, Biologics and Drug Delivery revenue is estimated at $5 million, Capital and Software at $7.4 million, and Functional Neurosurgery at $3.6 million [35]

●● ..... ..... ●● CLEARPOINT® NEURO WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY." Nasdaq: CLPT May 2021 Forward Looking Statements Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statement ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2021 was $4 million, an increase of 29% from $3.1 million in Q1 2020, reflecting a growth of $0.9 million [6][5][4] - Gross margin decreased to 65% in Q1 2021 from 70% in Q1 2020, primarily due to a higher contribution of service revenue in the previous year [10] - Cash and cash equivalents increased to $64.9 million as of March 31, 2021, compared to $20.1 million a year earlier, largely due to a public offering [13] Business Line Data and Key Metrics Changes - Functional neurosurgery navigation revenue increased by 10% to $1.9 million in Q1 2021 from $1.7 million in Q1 2020, driven by the resumption of elective surgical procedures [7] - Biologics and drug delivery revenue surged by 61% to $1.7 million in Q1 2021 from $1 million in Q1 2020, attributed to the resumption of clinical trial activities [8] - Capital equipment and software revenue rose by 31% to $0.5 million in Q1 2021 from $0.3 million in Q1 2020, reflecting a partial recovery in hospital capital equipment acquisition [9] Market Data and Key Metrics Changes - The company reported a significant increase in case volume, with 214 cases covered in Q1 2021, exceeding the prior estimate of 190 to 200 cases [14] - The company anticipates revenue for the full year 2021 to be in the range of $16 million to $17.5 million, with case volume expected to be between 900 and 1000 cases [23] Company Strategy and Development Direction - The company is focused on four pillars of growth: functional neurosurgery navigation, biologics and drug delivery, ClearPoint owned therapeutic products, and achieving global scale [4] - The FDA clearance for the Array navigation system is a significant milestone, with plans for a limited market release in the second quarter of 2021 [15] - The company aims to expand its presence in Europe and has successfully obtained CE Mark for several products, indicating readiness for compliance with new European MDR guidelines [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery of elective procedures and the return of case volumes to pre-pandemic levels [14] - The company is preparing for potential commercial launches in 2022, with ongoing support for multiple partners [31] - Management acknowledged challenges related to capital equipment timing and the initiation of new pharma trials, which could affect revenue recognition [24][25] Other Important Information - Research and development costs increased by 91% to $1.6 million in Q1 2021, reflecting investments in expanding product lines and international compliance [11] - General and administrative expenses rose by 30% to $1.7 million in Q1 2021, primarily due to increased insurance and occupancy costs [12] Q&A Session Summary Question: Insights on the uptick in biologics and drug delivery revenue - Management noted that the increase was driven by the resumption of clinical trials and preclinical work, including toxicology studies [28] Question: Guidance on biologics and drug delivery disposables - Management indicated that revenue can be choppy due to milestone payments and large orders, but expects stabilization as more partners are added [29] Question: Status of commercial launch preparations - Management confirmed ongoing preparations for commercial releases, with expectations for a 2022 launch [31] Question: Importance of SmartFrame Array FDA clearance - Management emphasized that the SmartFrame Array allows for a more integrated workflow in both operating rooms and MRI suites, expanding market opportunities [39] Question: Details on the D&K Engineering partnership - Management clarified that the partnership focuses on automating mundane parts of procedures to improve efficiency and precision [44] Question: Revenue and EBITDA margin targets for the next few years - Management refrained from providing specific targets but indicated a base growth of 15% to 20% annually, with potential for larger revenue-driving milestones [70][72]